What Analysts Recommend for Tilray in April

Tilray (TLRY) is turning out to be one of the worst performers among the cannabis sector players with a YTD loss of 16%. In comparison, peer (HMMJ) Canopy Growth (WEED) was up about 60%, Aurora Cannabis (ACB) was up 81%, and Aphria (APHA) was up nearly 70% in the same period. Let’s look at how analysts’ ratings changed over the last month.

WAKE UP WITH BAGELS & STOX, OUR NEW EMAIL THAT ENTERTAINS AND INFORMS YOU BEFORE THE DAY STARTS. SIGN UP HERE!

As the above chart shows, the consensus recommendation of the 11 analysts covering the stock remained unchanged month-over-month at a “hold.” Out of those 11 analysts, none had a “strong buy” on the stock, but three analysts continued to recommend a “buy” this month. Also, four analysts continued to recommend a “hold” on Tilray, and two analysts recommended a “sell” on the stock. One analyst maintained a “strong sell” recommendation for Tilray. Over the last three months, analysts have turned relatively bearish on Tilray.

The current consensus price target of $107.7 for Tilray was also lower than last month’s consensus target of $117.2. The company’s target has come down considerably from the peak of about $147 just about six months ago, as the company has continued to disappoint investors. Tilray closed at $59.5 on April 5, which would leave an upside of about 80% if analysts turn out to be right.